Eisner Devon Roshan, Hui Ada, Eppler Kirk, Tegoulia Vassia, Maa Yuh-Fun
Pharmaceutical Processing and Technology Development, Genentech, a Member of the Roche Group, 1 DNA Way South San Francisco, CA 94080; and.
Late Stage Pharmaceutical Development, Genentech, a Member of the Roche Group, 1 DNA Way, South San Francisco, CA 94080.
PDA J Pharm Sci Technol. 2019 May-Jun;73(3):285-291. doi: 10.5731/pdajpst.2018.009340. Epub 2019 Jan 16.
During the manufacture of a monoclonal antibody drug product, which was aseptically filled within a vapor phase hydrogen peroxide-sanitized isolator, samples were taken to investigate the hydrogen peroxide uptake behaviors. Surprisingly, the samples had no detectable hydrogen peroxide (most results below the limit of detection). This finding was later attributed to hydrogen peroxide decomposition after the samples were stored frozen at -20°C for two weeks before testing. This case study highlights the criticality of storage conditions for hydrogen peroxide-containing samples and summarizes an investigation on hydrogen peroxide stability in water and in three monoclonal antibody solutions having a wide protein concentration range (30-200 mg/mL). Samples were stored at three temperatures (-70°C, -20°C, or 2-8°C) for up to 28 days to assess the impact of protein concentration and storage temperature on hydrogen peroxide decomposition rates. Hydrogen peroxide degraded slightly more rapidly with increasing protein concentration independent of storage condition. When stored at -20°C, hydrogen peroxide was least stable and degraded faster than when stored at 2-8°C. Hydrogen peroxide was most stable when the samples were stored at -70°C. Overall, this case study brings the hydrogen peroxide stability issue to the attention of process development scientists and engineers and offers a valuable lesson learned during process development. The use of vapor phase hydrogen peroxide as a sanitizing agent for isolator and cleanroom decontamination has become common in recent years. Because of the potential impact of residual hydrogen peroxide on biopharmaceutical product quality, hydrogen peroxide uptake behaviors and mechanisms during the manufacturing process within these barriers need to be evaluated and understood. Samples taken from various small-scale and manufacturing-scale hydrogen peroxide uptake studies are often stored frozen before testing. This case study reports an important and interesting finding about hydrogen peroxide stability in samples collected for hydrogen peroxide uptake investigation, and it demonstrates the relationship between hydrogen peroxide stability and storage temperature, storage duration, and monoclonal antibody concentration. The approach and outcome of this study are expected to benefit scientists and engineers who develop biologic product manufacturing processes by providing a better understanding of drug product process challenges and appropriate sample storage.
在一种单克隆抗体药物产品的生产过程中,该产品在气相过氧化氢消毒的隔离器内进行无菌灌装,期间采集了样本以研究过氧化氢的吸收行为。令人惊讶的是,样本中未检测到过氧化氢(大多数结果低于检测限)。这一发现后来归因于样本在测试前于-20°C冷冻保存两周后过氧化氢发生了分解。本案例研究突出了含过氧化氢样本储存条件的重要性,并总结了一项关于过氧化氢在水和三种蛋白质浓度范围较宽(30 - 200 mg/mL)的单克隆抗体溶液中的稳定性研究。样本在三个温度(-70°C、-20°C或2 - 8°C)下储存长达28天,以评估蛋白质浓度和储存温度对过氧化氢分解速率的影响。过氧化氢随蛋白质浓度增加而降解略快,与储存条件无关。当在-20°C储存时,过氧化氢最不稳定,降解速度比在2 - 8°C储存时更快。当样本在-70°C储存时,过氧化氢最稳定。总体而言,本案例研究使过氧化氢稳定性问题引起了工艺开发科学家和工程师的关注,并提供了工艺开发过程中的宝贵经验教训。近年来,使用气相过氧化氢作为隔离器和洁净室去污的消毒剂已变得很普遍。由于残留过氧化氢对生物制药产品质量的潜在影响,需要评估和了解这些屏障内制造过程中过氧化氢的吸收行为和机制。从各种小规模和生产规模的过氧化氢吸收研究中采集的样本在测试前通常会冷冻保存。本案例研究报告了关于为过氧化氢吸收调查而采集的样本中过氧化氢稳定性的一项重要且有趣的发现,并展示了过氧化氢稳定性与储存温度、储存持续时间和单克隆抗体浓度之间的关系。预计本研究的方法和结果将使开发生物产品制造工艺的科学家和工程师受益,帮助他们更好地理解药品工艺挑战并进行适当的样本储存。